To Curb Imports, Bio Farma Pushes Local Content to 71%

Jakarta, CNBC Indonesia – Bio Farma Chief Executive Shadiq Akasya has confirmed that the Domestic Content Level (TKDN) of its products has reached 71%. This demonstrates that the company’s dependence on imports has declined in recent years.

“There are indeed some raw materials that we cannot yet produce ourselves. However, through the group, 19 molecules have been provided for domestic needs,” Shadiq explained to CNBC Indonesia on Monday (7/9/2026).

He went on to say that, in order to strengthen vaccine resilience going forward, Bio Farma will continue developing molecules so that at least domestic demand for medicines can be met independently.

“There are products we can already produce ourselves, but there are also those for which we still require supplies due to demand or regulatory requirements,” Shadiq clarified.

For context, Bio Farma continues to conduct research and collaborate with universities both at home and abroad on a range of vaccines. At the same time, Shadiq affirmed that the company will keep producing essential vaccines for the domestic market, such as those for polio, tetanus and diphtheria, amongst others.

“We will continue developing so that we can export whilst still fulfilling our domestic obligations,” Shadiq asserted.

Beyond new product development, Bio Farma also has the opportunity to optimise its clinical trial business. A clinical trial is the experimental process conducted before a health product is registered and sold commercially.

The clinical trial stage follows preclinical testing, under the WHO Listed Authority (WLA) status granted to Indonesia’s BPOM by the World Health Organization (WHO).

Bio Farma itself already possesses competent clinical testing facilities ready for use by global companies under BPOM supervision, from preclinical testing and clinical trials through to registration.